Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Current Assets: 2011-2025

Historic Current Assets for Mimedx Group (MDXG) over the last 14 years, with Sep 2025 value amounting to $254.1 million.

  • Mimedx Group's Current Assets rose 47.61% to $254.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.1 million, marking a year-over-year increase of 47.61%. This contributed to the annual value of $191.9 million for FY2024, which is 16.82% up from last year.
  • Per Mimedx Group's latest filing, its Current Assets stood at $254.1 million for Q3 2025, which was up 15.04% from $220.9 million recorded in Q2 2025.
  • Mimedx Group's 5-year Current Assets high stood at $254.1 million for Q3 2025, and its period low was $131.0 million during Q2 2022.
  • Its 3-year average for Current Assets is $174.9 million, with a median of $164.3 million in 2023.
  • In the last 5 years, Mimedx Group's Current Assets declined by 17.25% in 2021 and then skyrocketed by 47.61% in 2025.
  • Quarterly analysis of 5 years shows Mimedx Group's Current Assets stood at $148.5 million in 2021, then dropped by 9.64% to $134.2 million in 2022, then climbed by 22.40% to $164.3 million in 2023, then grew by 16.82% to $191.9 million in 2024, then soared by 47.61% to $254.1 million in 2025.
  • Its Current Assets stands at $254.1 million for Q3 2025, versus $220.9 million for Q2 2025 and $200.1 million for Q1 2025.